Please assess the completion status of the following clinical trial:

Trial Title: Iduronate-2-sulfatase Enzyme Replacement Therapy in Mucopolysaccharidosis II (MPS II)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~To be eligible to participate in this study, patients must meet the following inclusion criteria prior to enrollment:~1. The diagnosis of MPS II will be determined by the investigator based upon both clinical and biochemical criteria.~2. All patients must have at least one of the following Clinical Criteria considered by the investigator to be MPS II-related:~   * Hepatosplenomegaly~  * Radiographic evidence of dysostosis multiplex~  * Valvular heart disease~  * Evidence of obstructive pulmonary disease~3. In addition, patients must have the following Biochemical Criteria:~   * Documented deficiency in iduronate-2-sulfastase enzyme activity of less than or equal to 10% of the lower limit of the normal range as measured in plasma, fibroblasts, or leukocytes (based on normal range of measuring laboratory).~  * A normal enzyme activity level of one other sulfatase as measured in plasma, fibroblasts, or leukocytes (based on normal range of measuring laboratory).~4. Must be male, 5 to 25 years of age.~5. Forced vital capacity of \<80% of predicted obtained at the baseline evaluation of this study.~6. Must be able to adequately perform the testing required in this study, including reproducible pulmonary function testing by spirometry, as judged by the investigator.~7. Patient, patient's parent(s), or legally authorized guardian must have voluntarily signed an Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved informed consent form after all relevant aspects of the study have been explained and discussed with the patient.~Exclusion Criteria:~Patients meeting any of the following criteria are not eligible for participation in this study:~1. Patient has received treatment with another investigational therapy within the past 60 days.~2. Patient, patient's parent(s), or patient's legal guardian is unable to understand the nature, scope, and possible consequences of the study.~3. Patient is unable to comply with the protocol (e.g., due to a medical condition such as cervical cord compression or uncooperative attitude) or is unlikely to complete the study, as determined by the investigator.~4. Patient has a tracheostomy.~5. Patient has received a bone marrow or cord blood transplant.~6. Patient with known hypersensitivity to any of the components of iduronate-2-sulfatase.

- Gender: MALE
- Minimum Age: 5 Years
- Maximum Age: 25 Years
- Healthy Volunteers: f

Study Arms:
- Idursulfase weekly (0.5 mg/kg) (Type: EXPERIMENTAL): None
- Idursulfase every other week (0.5 mg/kg) (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).